Table 2.
Acquisition of Subcutaneous Growth Properties of QR-32 Tumor Cells Injected after Admix with Early-Phase of Gelatin Sponge-Infiltrated Inflammatory Cells
| No. of QR-32 cells | Inflammatory cells obtained from | No. of mice with tumor/no. of mice injected* | Mean survival time | ||
|---|---|---|---|---|---|
| Exp. I | Exp. II | Total | |||
| 1 × 105 | - | 0/10 | 0/10 | 0/20 (0%) | - |
| 1 × 105 | Day 5 gelatin sponge | 6/12 | 5/10 | 11/22† (50%) | 51.8 ± 5.3 |
| 1 × 105 | Day 10 gelatin sponge | 2/12 | 3/10 | 5/22‡ (23%) | 53.4 ± 6.8 |
| 1 × 105 | Day 20 gelatin sponge | 1/12 | 0/10 | 1/22§ (5%) | 53 |
| 1 × 105 | Day 30 gelatin sponge | NA | NA | NA | NA |
| 1 × 105 | Neutrophils purified from bone marrow | 1/10 | 1/19 | 2/19§ (11%) | 58.5 ± 7.8 |
*Gelatin sponge was inserted into the subcutaneous space of mice. The sponge was removed as indicated days and infiltrated cells were collected. QR-32 cells (1 × 105 cells) were admixed with or without 1 × 106 cells of gelatin sponge-infiltrated cells or neutrophils obtained from bone marrow, and then injected subcutaneously into mice.
†P < 0.001;
‡P < 0.05;
§not significant versus QR-32 cells alone.